Proficio Capital Partners LLC Acquires New Position in Ascendis Pharma A/S (NASDAQ:ASND)

Proficio Capital Partners LLC bought a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 12,528 shares of the biotechnology company’s stock, valued at approximately $1,725,000.

Other large investors also recently bought and sold shares of the company. Thrivent Financial for Lutherans grew its holdings in shares of Ascendis Pharma A/S by 0.3% during the third quarter. Thrivent Financial for Lutherans now owns 78,473 shares of the biotechnology company’s stock valued at $11,717,000 after buying an additional 228 shares during the last quarter. Avior Wealth Management LLC increased its holdings in shares of Ascendis Pharma A/S by 3.0% in the third quarter. Avior Wealth Management LLC now owns 8,212 shares of the biotechnology company’s stock valued at $1,226,000 after purchasing an additional 240 shares during the period. Advisors Asset Management Inc. lifted its holdings in shares of Ascendis Pharma A/S by 23.2% during the third quarter. Advisors Asset Management Inc. now owns 4,742 shares of the biotechnology company’s stock worth $708,000 after purchasing an additional 894 shares during the period. Massachusetts Financial Services Co. MA boosted its position in Ascendis Pharma A/S by 9.1% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock valued at $278,760,000 after buying an additional 155,971 shares during the last quarter. Finally, Valence8 US LP acquired a new position in Ascendis Pharma A/S in the 3rd quarter worth approximately $685,000.

Wall Street Analysts Forecast Growth

ASND has been the subject of several research reports. The Goldman Sachs Group lifted their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. Morgan Stanley set a $180.00 price target on Ascendis Pharma A/S in a research report on Tuesday, February 18th. Cantor Fitzgerald boosted their price objective on Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an “overweight” rating in a report on Tuesday, February 25th. StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, UBS Group assumed coverage on shares of Ascendis Pharma A/S in a research note on Tuesday, January 7th. They issued a “buy” rating and a $196.00 target price for the company. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, Ascendis Pharma A/S has an average rating of “Moderate Buy” and a consensus price target of $204.64.

Ascendis Pharma A/S Trading Up 0.9 %

NASDAQ:ASND opened at $166.05 on Thursday. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $169.37. The company has a market cap of $10.08 billion, a P/E ratio of -23.39 and a beta of 0.62. The company’s 50-day moving average price is $140.06 and its 200-day moving average price is $135.30.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($1.32) by $0.64. On average, analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.